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Summary
Significance: Obesity and type 2 diabetes mellitus are increasing globally. There is also
increasing associated complications, such as non-alcoholic fatty liver disease (NAFLD) and
vascular complications of diabetes. There is currently no licensed treatment for NAFLD and
no recent treatments for diabetic complications. New approaches are required, particularly
addressing mechanism-based risk factors for health decline and disease progression.
Recent advances: Dicarbonyl stress is the abnormal accumulation of reactive dicarbonyl
metabolites such as methylglyoxal leading to cell and tissue dysfunction. It is a potential
driver of obesity, diabetes and related complications unaddressed by current treatments.
Increased formation of methylglyoxal is linked to increased glyceroneogenesis and
hyperglycemia in obesity and diabetes and also down-regulation of glyoxalase 1 (Glo1) –
which provides the main enzymatic detoxification of methylglyoxal. Glo1 functional
genomics studies suggest increasing Glo1 expression and activity alleviates dicarbonyl stress
and slows development of obesity, related insulin resistance and prevents development of
diabetic nephropathy and other microvascular complications of diabetes. A new therapeutic
approach is small molecule inducers of Glo1 expression - Glo1 inducers - exploiting a
regulatory antioxidant response element in the GLO1 gene. A prototype Glo1 inducer, trans-
resveratrol-hesperetin combination, in clinical trial corrected insulin resistance, improved
glycemic control and vascular inflammation in healthy overweight and obese subjects.
Critical issues: trans-Resveratrol and hesperetin synergise pharmacologically and hesperetin
likely overcomes the low bioavailability of trans-resveratrol by inhibition of intestinal
glucuronosyltransferases.
Future directions: Glo1 inducers may now be evaluated in Phase 2 clinical trial for treatment
of NAFLD and vascular complications of diabetes.
Key words: methylglyoxal, glycation, insulin resistance, NAFLD, diabetic complications,
resveratrol.
2Health impact of obesity and diabetes and the related hepatic and vascular
complications –time for improved, safe and effective treatment
There are > 2.1 billion people worldwide who are overweight or obese. The prevalence is ca.
37% in the adult population and 13% in adolescents and children in developing countries and
23% in developed countries. Obesity is increasing globally: the highest prevalence is in
Western Pacific Island nations and the Middle East where the current prevalence is 50 – 70%
of the population. The countries the highest number of obese people, in decreasing order, are:
USA, China, India, Russia, Brazil and Mexico; and 62% of the global obese population live
in developing countries (121). There are currently an estimated 415 million people with
diabetes worldwide; of these, ca.90% is type 2 diabetes mellitus (T2DM) and 10% type 1
diabetes mellitus (T1DM) (76). Global prevalence of patients with T2DM parallels that of
obesity. Countries with the highest prevalence of T2DM are the Western Pacific Island
nations and countries of the Middle East; countries with the highest number of T2DM
patients, by decreasing order, are: China (101 million), India (69 million), USA (24 million)
and Brazil (14 million). The region with the highest number of patients with T2DM is the
Western Pacific with 153 million. Sub-Saharan Africa is the region with the highest level of
undiagnosed diabetes – estimated at 80% of people with diabetes (76). Premature death and
loss of productive life in obesity and diabetes is caused mainly by common co-morbidities –
metabolic and vascular complications. Obesity, diabetes and their co-morbidities increase
with age and their prevalence is likely to increase in the next 10 – 20 years in the aging
populations of many countries.
In 2010 being overweight and obese was estimated to cause 3.4 million deaths
worldwide. Most deaths are due to cardiovascular disease (CVD) – mostly manifested as
coronary heart disease (CHD) and stroke. The increased mortality risk of CHD and stroke is
attributed to hypertension and dyslipidemia (36% and 59%) and hyperglycemia (14% and
25%); with residual risk (50% and 16%) unexplained (101). A further complication in
overweight and obese subjects is non-alcoholic fatty liver disease (NAFLD) leading to
hepatic steatosis, cirrhosis, liver failure and cancer (81). NAFLD affects 20 – 40% of the
population in Westernised countries and will likely increase direct and indirect medical costs
by 25% in the next 5 years. A common metabolic complication in overweight and obese
subjects is insulin resistance. This drives the development of T2DM and also NAFLD.
Common complications of diabetes are: increased risk of CVD - CHD, peripheral artery
disease and stroke; and microvascular complications – nephropathy, retinopathy and
neuropathy. Diabetes increases mortality risk of CVD by 2 – 3 fold, increasing further to 3 - 6
fold in advanced diabetic nephropathy (63,89). There is an urgent requirement for improved
understanding of the risk factors of obesity, insulin resistance and NAFLD to guide
interventions to decrease incidence and health impact (200). There is also an urgent need to
improve therapy for diabetic nephropathy and other diabetic complications. It is 15 years
since clinical trials produced new drugs licensed for diabetic nephropathy and the current
survival of patients with diabetic nephropathy is similar to that of average survival of patients
with cancer (40).
The glyoxalase system and dicarbonyl stress - introduction
The glyoxalase system is a cytoplasmic enzyme system present in all mammalian cells. It
consists of two enzymes which catalyse successive enzymatic reactions, glyoxalase 1 (Glo1)
and glyoxalase 2 (Glo1), and a catalytic amount of reduced glutathione (GSH). Glo1
catalyses the isomerisation of the hemithioacetal formed non-enzymatically from reactive
dicarbonyl metabolite methylglyoxal (MG) and GSH to S-D-lactoylglutathione and Glo2
catalyses the hydrolysis of S-D-lactoylglutathione to D-lactate, reforming GSH consumed in
the Glo1-catalysed reaction (174) (Fig. 1).
3The primary function of the glyoxalase system is to metabolise MG and/or other
reactive acyclic α-oxoaldehyde metabolites, and thereby suppress them to low steady-state 
concentrations. MG is the most reactive and of highest endogenous flux; and so is often the
primary concern (146). Typical concentrations of MG are 100 – 200 nM in plasma and in 1 –
4 µM in tissue (148). MG is formed by trace level, spontaneous degradation of
triosephosphates and other minor pathways – reviewed in (153). MG is a potent glycating
agent, reacting non-oxidatively mainly with arginine residues of proteins to form the
hydroimidazolone adduct, MG-H1, and reacting with DNA to form mainly imidazopurinone
adduct, MGdG (6,182). Protein and DNA contents are 0.1 – 0.8 mmol/mol arg and ca.9
adducts per 106 nucleotides, respectively (Fig. 2). Abnormally high concentrations of MG,
and/or other reactive α-oxoaldehyde metabolites, is a dysfunctional metabolic state called 
“dicarbonyl stress” where dicarbonyl glycation is increased (149). In dicarbonyl stress,
increased formation of MG and/or decreased activity of Glo1 produces increased cellular and
extracellular concentrations of MG driving cell and tissue dysfunction. The terminal product
of the glyoxalase system metabolism of MG is D-lactate which is partly metabolised in
mammalian tissues by mitochondrial D-lactate dehydrogenase (174). Plasma D-lactate is a
surrogate indicator of increased flux of formation of MG.
The protection provided by the glyoxalase system against dicarbonyl stress is
important developmentally and functionally. Knockout of the GLO1 gene is embryonically
lethal unless induction of compensatory metabolism by aldoketo reductases occurs (11,117).
Silencing of Glo1 expression decreases lifespan and increases susceptibility to glucose
intolerance and oxidative stress in the nematode C aenorhabditis elegans model of ageing and
glucose toxicity (116,161). In endothelial cells, silencing of Glo1 changed expression of over
485 genes linked to the development of CHD (107). The related increase of MG-H1 residue
content of cell protein changed the levels of MG-modified and unmodified cellular and
extracellular matrix (ECM) proteins (168). MG-H1 is a quantitatively the major protein-
derived advanced glycation endproduct (AGE). MG glycation of proteins is frequently
directed to functional sites of proteins. There is loss of positive charge of modified arginine
residues, resulting in protein inactivation and dysfunction (140,146). The MG nucleotide
adduct, MGdG, is a quantitatively major nucleotide AGE. MG-derived nucleotide adducts are
mutagenic and may be linked to malignant transformation. Supporting this, Glo1 was a
tumour suppressor protein in a mouse model of hepatocellular carcinogenesis (182,202).
The historical development of the glyoxalase research, molecular characteristics of
glyoxalase enzymes, molecular physiological of glyoxalase metabolites and techniques
available to study the glyoxalase system – the glyoxalase researchers “toolkit” – have been
reviewed elsewhere recently (147,151-153,194).
In situ activity of Glo1 is directly proportional to the concentration of GSH; MG
metabolism by Glo1 is impaired by GSH decline in oxidative stress (1). Mitochondrial
proteins are targets of MG glycation which drives increased formation of reactive oxygen
species (ROS) (116). So dicarbonyl stress may be both consequence and cause of oxidative
stress. Dicarbonyl stress may be also initiated and sustained without oxidative stress: through
increased formation of MG from increased triosephosphate flux driven by increased glucose
metabolism in hyperglycemia and glyceroneogenesis in triglyceride synthesis in obesity; and
down-regulation of Glo1 linked to hypoxia (162), inflammatory signalling conflicting with
Nrf2 (193) and hyperglycemia-induced increased proteolysis (197). It is not surprising,
therefore, that dicarbonyl stress is beginning to feature strongly as a driver of pathogenesis in
obesity and diabetes – particularly vascular complications (62,107,111,184). A new type of
experimental therapeutic agent has emerged to counter dicarbonyl stress: an inducer of Glo1
expression or “Glo1 inducer” (195). We review the background to this development below.
4Beneficial effects of methylglyoxal formation for physiological function
There is no known direct benefit of MG formation for physiological function in mammals.
The major source of MG formation is spontaneous formation from triosephosphates,
dihydroxyacetonephosphate (DHAP) and glyceraldehyde-3-phosphate (GA3P). This occurs
as a consequence of the use of high energy triosephosphate intermediates in glycolytic
metabolism (136). MG modification of alpha-crystallin improved chaperone function and
protein refolding activity but this effect was limited to higher extents of protein modification
by MG than found physiologically (59). However, accumulation of MG is implicated in host
defence mechanisms – particularly anti-microbial activity of phagocytic cells. The cellular
concentration of GSH falls >90% during the activation of the phagocytic respiratory burst as
part of the biocidal activity against towards pathogenic micro-organisms (177). In situ
activity of Glo1 will decrease proportionately and local concentration of MG thereby
increases (1). The pentosephosphate pathway is also activated to produce increased flux of
NADPH to sustain NADPH oxidase activity during the respiratory burst (201) and becomes a
net producer of triosephosphates and hence also indirectly increases MG formation (133).
MG is expected to accumulate within activated phagocytic cells and be released into the
phagosome and therein modify proteins of engulfed micro-organisms. This suggests that MG
has a role in the anti-microbial activity of phagocytes - such as neutrophils, monocytes and
macrophages. Evidence for this has been reported recently (205). It may also play a role in
tissue damage in inflammation. Increased synovial and plasma levels of MG-derived AGEs
was a characteristic of advanced stages of arthritis (7).
In microbial metabolism there is enzymatic formation of MG from DHAP by MG
synthase (118). This provides a bypass for the lower half of the Embden-Meyerhof pathway.
Embden-Meyerhof glycolysis converts DHAP to pyruvate with formation of 2 equivalents of
ATP and one equivalent of NADH; whereas the MG synthase/glyoxalase/D-lactic
dehydrogenase bypass in micro-organisms achieves the same conversion without ATP
formation. In an ATP rich status, this facilitates supply of pyruvate to the citric acid cycle for
production of NADH to maintain microbial reducing status and fro production of GTP for
RNA and DNA synthesis and gluconeogenesis. This may provide micro-organisms with a
growth and survival advantage, particularly when growing on varied carbon source nutrients
(199).
Dicarbonyl stress and the glyoxalase system in obesity
The plasma concentration of MG in lean, healthy human subjects was 132 ± 63 nM (148).
This was increased to 181 ± 61 nM in overweight subjects and increased further to 245 ± 123
nM in obese subjects (111). The increases were sustained on an isocaloric diet. Plasma D-
lactate was increased in obese subjects – 6.5 versus 15.9 µM, but not in overweight subjects
(111,113). This suggests that as body mass index (BMI) increases, there is initially decreased
metabolism of MG by down regulation of Glo1 driving dicarbonyl stress in overweight
subjects; and thereafter also increased formation of MG in obesity, exacerbating dicarbonyl
stress further. Increased plasma D-lactate was linked to insulin resistance in obesity (106).
Other groups have found similar increases in plasma MG albeit with slightly higher absolute
levels of MG which are likely analytical method-related (104). In the high fat diet (HFD)-fed
mouse overfeeding model of experimental obesity, estimates of MG in white adipose tissue
(WAT) were ca. 3.0 μM  and 1.5 μM in HFD-fed and control-fed mice, respectively, 
suggesting that dicarbonyl stress is also present in this tissue (111). HFD-fed mice had
increased MG-H1 content of heart and liver, measured by immunoassay (93). Dicarbonyl
stress in obesity, as judged by these increases of MG in plasma and WAT, is moderate.
Nevertheless, recent profound improvement in clinical health when correcting dicarbonyl
stress of overweight and obese subjects in the Healthy Ageing Through Functional Food
5(HATFF or Hats-off) study, Clinicaltrials.gov; NCT02095873, suggests it may be functionally
important (195).
A genetic association of GLO1 with obesity was found in genetic linkage analysis and
anthropometric measurements (189). In mice, meta-analysis of 34 mouse cross-breeding
experiments linked GLO1 to body weight (190). Glo1 expression and activity is decreased in
WAT in HFD-fed mice (103). Glo1 protein was decreased 80% in the liver of the mouse
overeating model of obesity, leptin mutant (ob/ob) mice (160). Overexpression of Glo1 in
HFD-fed mice suppressed gain in body weight and adiposity with similar food consumption
as wild-type HFD-fed controls (103). Relatedly, mice with a preference for high energy-rich
diets without marked weight gain and health impairment have a relatively high expression of
Glo1 (144). This suggests that down regulation of Glo1 as well as increased formation of MG
contribute to dicarbonyl stress in obesity and overexpression of Glo1 can suppress health
impairment of the obese phenotype.
The origin of increased MG concentration in obesity is likely not an effect of
increased food consumption directly as plasma MG was increased in obese subjects on an
isocaloric diet (111). There is relatively low intake of MG in food and beverages compared to
endogenous formation (153). Dietary MG also has limited bioavailability and is metabolised
and/or reacts with protein in the intestinal lumen (42). Normally increased glucose
metabolism would be implicated in increased formation of MG but insulin resistance in
obesity suggests the usually dominant source of MG formation from increased flux through
anaerobic glycolysis may not be the culprit. Rather increased triosephosphate flux in
glyceroneogenesis associated with adipocyte expansion in obesity supporting increased fatty
acid esterification for triglyceride deposition is the likely source (53). Most triglyceride
synthesis involves glyceroneogenesis via triosephosphate intermediates (125) and
glyceroneogenesis is not limited because it uses pyruvate as the carbon source with
unrestricted entry and metabolism into major cell types experiencing insulin resistance – such
as adipocytes, hepatocytes and skeletal muscle cells (Fig. 3).
The drivers for down-regulation of Glo1 in WAT in obesity are unknown. Glo1 may
undergo post-translational modifications: C139 may form a mixed disulfide with GSH,
inhibiting Glo1 activity in vitro. Glo1 may be S-nitrosylated on C139 and is a substrate for
calcium, calmodulin-dependent protein kinase II, with phosphorylation at T107. There may
also be acetylation at K148 (102) and likely de-acetylation by cytosolic sirtuin-2 (154). Glo1
down-regulation in obesity may be driven through hypoxia signalling by hypoxia-inducible
factor-1α (HIF1α) which down-regulates Glo1 expression (162,204). During adipose tissue 
expansion, interstitial oxygen tension decreases and adipocytes have high HIF1α protein 
content driving increased adipose tissue vascularization. Visceral adipose tissue from human
obese subjects had high levels of HIF1α. In mice, HIF1α activation in visceral white 
adipocytes drives glucose intolerance, insulin resistance, and cardiomyopathy (87).
Adipocyte-specific deletion of HIF1α decreased HFD–induced adipose tissue inflammation 
and insulin resistance (92). There are also low levels of SIRT2 in adipose tissue in obesity.
Decreased SIRT2 leaves PPARγ coactivator 1α (PGC1α) acetylated, driving decreased 
expression of β-oxidation and mitochondrial genes leading to decreased fatty acid catabolism 
and thermogenesis.
The biochemical consequences of dicarbonyl stress in WAT are unknown but it may
contribute to insulin resistance, decreased adipokine expression and inflammation (103).
Recent research has also suggested that β-Klotho may be a target, leading to its down 
regulation and resistance to fibroblast growth factor-21 (FGF21) which is a major contributor
to insulin resistance (58,195,206) – see below.
Several studies have attempted to model dicarbonyl stress in obesity by administration
of exogenous MG. Difficulties performing such studies are lack of commercial availability of
6suitable high purity MG and an appropriate dose to administer. Commercial 40% MG
contains 9 – 17 mol% formaldehyde and many other compounds that potentially interfere in
studies of dicarbonyl stress (137). The flux of endogenous formation of MG is ca.3 – 6
mg/kg (ca.0.05% glycolytic rate, which is found similar in many cell types) (146).
Experimental studies have often used 10 – 20 fold higher than this – which likely approaches
and exceeds the upper limit of more severe dicarbonyl stress found in poorly-controlled
clinical diabetes and end stage renal disease (113,145). Infusion of MG (60 mg/kg/day) into
healthy rats induced impaired glucose tolerance, decreased glucose transporter GLUT-4,
phosphoinositide-3-kinase activity, and insulin-stimulated glucose uptake in adipose tissue
(44). Exogenous MG (50 – 75 mg/kg, daily, i.p.) induced insulin resistance in mice (123),
inhibited insulin-stimulated phosphorylation of protein kinase B and extracellular-regulated
kinase, contributing to insulin resistance in muscle cells (156). It also inhibited insulin-
induced insulin receptor substrate tyrosine phosphorylation and phosphatidylinositol 3-
kinase/protein kinase B pathway activation in pancreatic beta-cells (51), increased free fatty
acids, hypoadiponectinemia, hypoxia and macrophage recruitment of adipose tissue (112).
These MG administration models are likely exploring features of MG intoxication but some
of the features produced may be similar to those developing in obesity – although less severe.
Obesity has been implicated as a driver for chronic kidney disease (CKD) in the
general population. This is thought to occur through vasoconstriction of efferent renal blood
vessels and consequent glomerular hyperfiltration driving renal podocyte, mesangial cell and
tubular epithelial cell dysfunction. A link to increased leptin and decreased adiponectin has
been suggested (169). Dicarbonyl stress is implicated renal cell dysfunction in the
development of diabetic nephropathy – as reviewed (153), and may also contribute to the
development of obesity-linked CKD in the non-diabetic state.
Dicarbonyl stress may be a contributory mediator of obesity and insulin resistance and
thereby a risk factor for development of T2DM and complications of obesity such as
NAFLD, CHD, hepatocellular cancer and CKD (103,107,202).
Diabetes and diabetic vascular complications
The initial major clinical investigation of dicarbonyl stress in diabetes was a study of whole
blood MG concentrations and red blood cell glyoxalase-linked variables in patients with T1DM,
patients with T2DM and healthy controls (113). Blood samples were collected under casual
conditions – without specific control for fasting or postprandial states. Whole blood MG
concentration was increased 5 - 6 fold in patients with T1DM and 3 – 4 fold increase of whole
blood MG in patients with T2DM (Fig. 4). These were disproportionately high increases
compared to increase in blood glucose and D-lactate concentrations – both increased 2 – 3 fold.
The likely reflects both increased MG formation in hyperglycemia and decrease in Glo1 activity
at peripheral tissue sites (113).
Increased plasma MG and D-lactate in clinical diabetes was confirmed by others and is
typical of the diabetic state, increased in fasting hyperglycemia and increasing further in the
postprandial period linked to the extent of hyperglycemia (20,21,105,170). Increased D-lactate
may also be detected in urine of patients with diabetes (170) whereas there is very little urinary
excretion of MG (42). Increased plasma MG is also found in the postprandial state in impaired
glucose tolerance of prediabetes (105). Pathogenic relevance has been indicated through plasma
MG correlating with risk of hypertension, arterial intima-media thickening in diabetic CVD and
also MG being linked to the presence and risk of progression of diabetic nephropathy
(67,78,127). Plasma levels of MG-derived glycation adducts are associated with risk of
developing diabetic nephropathy and CVD (19,71,124).
Studies of rodent models of diabetes have found evidence of increased MG in plasma
and tissues suffering vascular complications – kidney and peripheral nerve (13,23,29,30,60).
7Evidence of increased MG in the diabetic retina is difficult to obtain as MG leaks out of retinal
tissue during isolation. There was increased MG-H1 and other MG-derived glycation adducts in
protein of plasma, kidney, retina and peripheral nerve in experimental diabetes (13,80). The
functional significance of dicarbonyl stress and increased MG-driven protein glycation in these
tissues was indicated by prevention of diabetic nephropathy, retinopathy and neuropathy by
overexpression of Glo1 (22,23,30) and by therapeutic intervention to decrease MG formation
(13,70). Also, a mouse model of Glo1 deficiency developed a diabetic nephropathy-like
phenotype in normoglycemia and accelerated diabetic nephropathy when diabetes was induced.
Overexpression of Glo1 limited to vascular endothelial and renal proximal tubular cells also
prevented the development of diabetic nephropathy (62). Dosing of atherosclerosis susceptible
apolipoprotein E-deficient mice with the cell permeable Glo1 inhibitor, S-p-
bromobenzylglutathione cyclopentyl diester (178), increased endothelial inflammation and
atherogenesis similar to that observed in diabetes (184). These studies suggest dicarbonyl
stress is a driver for diabetic microvascular and macrovascular complications.
Dicarbonyl stress is exacerbated in diabetes by down regulation of Glo1 in the kidney,
retina and peripheral nerve, and likely also vascular endothelial cells (23,114,197). This may
reflect decreased Glo1 expression in response to inflammatory signalling induced by the
receptor for advanced glycation endproducts (RAGE) and other mechanisms (155), NF-κB 
conflicting with Nrf2 which regulates basal and inducible expression of Glo1 (97,193), and also
hyperglycemia-induced increased proteolysis of Glo1 (197).
Dicarbonyl stress may promote the development of vascular complications through
protein glycation linked to: ECM protein modification leading to cell detachment and
dysfunction (45,138) and changes in ECM synthesis and processing (168), mitochondrial protein
modification driving increased ROS formation and oxidative stress (158), modification of p300
and p65 of HIF1α and NF-κB signalling pathways driving abnormal responses to ischaemia and 
persistent vascular inflammation (173,197), modification of the 20S proteasome and slowing of
cellular proteolysis (139), modification of lipoproteins driving dyslipidemia and atherosclerosis
(64,141), β-Klotho depletion driving inflammation, insulin resistance and nephropathy (206), 
and other processes.
Development of therapeutic agents to counter dicarbonyl stress
Strategies to prevent dicarbonyl stress for therapeutic application are: (i) compounds that
prevent dicarbonyl formation – such as high dose thiamine therapy for MG-linked dicarbonyl
stress in diabetes; (ii) compounds that react rapidly with dicarbonyls to outcompete with
endogenous proteins in situ – Dicarbonyl scavengers; and (iii) compounds which correct
Glo1 deficiency in obesity and diabetes by inducing its expression, “Glo1 inducers”.
P revention of methylglyoxalformation by highdose thiamine therapy
The major source of formation of MG in physiological systems is degradation of
triosephosphates (136). Interventions to prevent the abnormal accumulation of
triosephosphates in diabetes are expected to decrease MG formation. A strategy explored to
achieve this was to increase activity of transketolase and thereby stimulate the reductive
pentosephosphate pathway which operates with net consumption of GA3P and fructose-6-
phosphate with conversion to ribose-5-phosphate. Initial studies in cultured cells showed that
this intervention was achievable, albeit at high, supraphysiological concentrations (180). This
was later translated to the pre-clinical model of streptozotocin (STZ)-induced diabetic rats
where 7 mg/kg and 70 mg/kg thiamine decreased plasma MG, tissue and protein glycation by
MG in plasma and tissues at sites of microvascular complications development (13,14,80).
Thiamine therapy reversed increases of plasma and urinary D-lactate in STZ diabetic rats,
consistent with the treatment decreasing the flux of MG formation (79). The study of
8thiamine metabolism in STZ diabetic rats revealed that diabetes produced increased renal
clearance of thiamine and imposed a tissue-specific thiamine deficiency (13). Increased renal
clearance of thiamine was also found in diabetic patient groups in United Kingdom and
Pakistan although increased thiamine clearance was less marked in diabetic patients in
Indonesia. The reason for this difference is unknown; vascular inflammation was also
markedly lower in diabetic patients in Indonesia (2,12,142). Increased renal clearance of
thiamine appears to be produced by glucose-induced down regulation of expression of renal
tubular thiamine transport proteins (90). High dose thiamine supplements prevented and
reversed early-stage diabetic nephropathy in pre-clinical and clinical studies and improved
glucose tolerance in a study group of subjects with mainly impaired glucose tolerance
(8,142,164). High dose thiamine therapy may also be effective against other vascular
complications of diabetes – reviewed in (143). Therapeutic benefit may not be generally
available to the healthy population where tissues are likely replete with thiamine. A recent
study has suggested in renal failure the thiamine anti-metabolite oxythiamine accumulates
which may also impair transketolase function and contribute to triosephosphate accumulation
and increased formation of MG (203).
Dicarbonyl scavengers
Scavengers of dicarbonyl compounds may potentially decrease plasma and tissue
concentrations of all α-oxoaldehyde metabolites – although they tend to be more effective 
against reactive acyclic dicarbonyls such as glyoxal and MG and less effective against α-
oxoaldehydes of lower reactivity with major cyclic hemiacetal solution species, such as 3-
deoxyglucosone (183). A disadvantage is that removal of dicarbonyls is stoichiometric; cf.
scavenging of ROS by α-tocopherol, ascorbic acid and GSH which has reductive regeneration 
and cycling of the antioxidant in cells and body fluids under normal physiological function
(39,94,96). Several approaches have been explored (Fig. 5).
A minogu anidine (P imagedine)
The initial experimental therapeutic developed for treatment of vascular complications of
diabetes that has dicarbonyl scavenging activity is aminoguanidine (Pimagedine).
Aminoguanidine was initially thought to react with fructosamine residues and prevent
formation of AGEs (31) but lack of effect on fructosamine levels in glycated proteins in vivo
suggested that other mechanisms of intervening in glycation processes may be involved (43).
Aminoguanidine rather reacts with MG and other dicarbonyls to form 3-amino-1,2,4-triazine
derivatives (3,183). It was ca.100-fold more effective than arginine in preventing glycation
of plasma protein in an ex vivo system mimicking physiological glycation – human plasma
without significant dilution at 37 oC with 1 μM [14C]MG (99). The reaction kinetics of MG
with aminoguanidine are complex because there are two parallel reaction pathways: (i)
reaction of aminoguanidine with the unhydrated form of MG forming 5-methyl-3-amino-
1,2,4-triazine, and (ii) reaction of aminoguanidine with the MG monohydrate forming 6-
methyl-3-amino-1,2,4-triazine (183). Under physiological conditions of <10 μM MG and 
peak plasma aminoguanidine of ca. 50 – 60 μM, the major reaction is via the former reaction 
pathway (183). In healthy human subjects, an oral dose of 300 mg per day aminoguanidine
achieved a peak plasma concentration of ca. 50 μM with half-life of ca.1.4 h (126); and in
patients with end stage renal disease receiving haemodialysis renal replacement therapy, the
peak plasma concentration was 61 μM with a half-life of 37.9 h between dialysis and ca.1.5
h  whilst on haemodialysis (52). Plasma concentrations of  up to 400 μM have been achieved 
experimentally in rats after intraperitoneal injection of 100 mg/kg aminoguanidine (43). The
estimated rate of formation of MG-derived glycation adducts of plasma protein in human
plasma in situ  is 0.58 μMday-1 (148,176) and the estimated rate of reaction of 50 μM 
9aminoguanidine with physiological concentrations of MG (100 nM) is 0.86 μMday-1 (183).
So, at its peak plasma concentration, aminoguanidine is an effective MG scavenger. In
contrast, inside cells aminoguanidine is predicted to compete very ineffectively with Glo1 for
MG scavenging. Even at high experimental doses up to ca.400 mg/kg aminoguanidine
achieving tissue concentrations of 200 µM – 1 mM aminoguanidine, in situ Glo1 activity is
predicted to scavenge MG >1000 fold faster than aminoguanidine (126,175).
Problems associated with aminoguanidine development in clinical trial were adverse
effects (gastrointestinal disturbance, abnormalities in liver function tests, ﬂu-like symptoms, 
and a rare vasculitis) (54) and failure to meet the clinical endpoint in evaluation for treatment
of diabetic nephropathy (25). Clinical therapeutic development was questioned further when
renal tumours were found in aminoguanidine-treated diabetic rats (130). The rapid clearance
of aminoguanidine impaired its clinical efficacy and, with toxicity and adverse effects, further
clinical development is unlikely.
Dicarbonyl scavenging likely contributed to the experimental prevention of vascular
complications of diabetes by aminoguanidine – reviewed in (175), and obesity (57,163). At
pharmacologically relevant concentrations in vivo, aminoguanidine is also an inhibitor of
inducible nitric oxide synthase (iNOS), Ki = 31 μM; although it is probably not an inhibitor 
of neuronal nitric oxide synthase (nNOS), Ki = 170 μM, and endothelial nitric oxide synthase 
(eNOS), Ki = 330 μM in vivo (9). At very high supra-physiological concentrations of
aminoguanidine there are also significant reactions with pyruvate and glucose for which
effective median inhibitory concentration IC50 values were estimated to be 7 mM and 59 mM,
respectively (175). In vitro studies of cell systems using aminoguanidine concentrations of
>50 – 100 μM likely compromise physiological relevance for dicarbonyl scavenging effects.  
M etformin
Metformin is a therapeutic agent widely used for the treatment of patients with T2DM. It has
long been considered to work by decreasing hepatic glucose production, improving glucose
uptake and utilization (65). Recent studies suggest decreased hepatic glucose production may
occur through activation of duodenal AMP-activated protein kinase (AMPK)–dependent
pathway (46). It has also found to be of benefit but is not in widespread use for treatment of
prediabetes in obesity (131). It was associated with decreased plasma MG concentration in
patients with T2DM (20), and also decreased plasma protein glycation by MG – including
MG glycation of LDL (150). It reacts with MG to form mainly hydroimidazolone and also
triazepinone adducts (159). These adducts are detected in vivo but they are quantitatively
minor compared to the flux of MG formation (18,85). The peak plasma concentration of
metformin is 23 µM at the 1.5g dose but may be ca.4 mM in the jejunum after ingestion
(66). The kinetics of the reaction of MG with metformin are relatively slow (15). It is likely,
therefore, that metformin decreases MG formation exposure by both improving glycaemic
control in diabetes and prediabetes and also has a weak MG scavenging activity.
P henacylthiazoliu m bromide
Phenacylthiazolium bromide (PTB) was developed as a prototype therapeutic agent for the
cleavage of putative α,β-carbonyl AGE protein crosslinks (188). Subsequent studies revealed 
instability of PTB and misinterpretation of some of the effects observed (181). PTB is an
efficient scavenger of MG; we found it was approximately 6-fold more effective than
aminoguanidine under physiological conditions, corroborated by others (84,183). PTB is,
however, unstable under physiological conditions and degrades by hydrolysis with a half-life
of 44 min (181). The pharmacokinetics of PTB have not been published but those of a
similar compound, TRC4186, found the peak plasma concentration was ca. 3 μM at dose of 
2500 mg with a half-life of 2 – 3 h (32). The short half-life and instability of this type of
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compound impairs the MG scavenging activity although this may have contributed to
beneficial effects found (38).
A rginine-richpeptides
Arginine and arginine-rich peptides are potential scavengers of MG and other dicarbonyls.
However, they have to achieve and maintain high steady-state concentrations in vivo to
outcompete with endogenous cellular and extracellular arginine residue concentration: ca.20
mM and 80 mM respectively (129,135). Arginine itself has poor scavenger activity with an
IC50 of 23 mM for plasma protein glycation by MG in the ex vivo model (100). Clinical
pharmacokinetics of arginine indicates that oral high dose arginine achieves a peak plasma
concentration of ca.300 µM and is an ineffective dicarbonyl scavenger (171). Arginine
residues may be made more reactive for scavenging of MG by decrease of the side chain pKa
with a proximate positivity charged amino acid residue. Improved MG scavenging has been
found with arg-arg and arg-lys residue containing peptides and with a large 40 amino acid
long peptide (GERP10) (23,28).
H istidine glyoxalase mimetics
In an attempt to produce catalytic scavengers of MG we explored the possibility of histidine
containing peptides, building on the prior observation that imidazole has a Glo1 mimetic
activity by reaction with MG and isomerisation to N-lactoylimidazole (69). We hypothesised
that the imidazole moiety of histidine and histidyl peptides may react with MG to form N-
lactoylimidazole derivatives and this would be hydrolysed by endogenous esterase activity in
plasma and tissues. The esterase site of albumin, for example, has N-acylimidazole hydrolase
activity (128). Histidine and β-alanylhistidine (carnosine) had Glo1 mimetic activity but the 
kinetics of MG scavenging is low such that at physiological concentrations of histidine in
plasma (270 µM), carnosine in skeletal muscle (10 mM) and typical Glo1 and GSH content
of mammalian cells, the reaction of MG is 260,000 and 20,000 fold faster with Glo1 than
with histidine and carnosine in situ (16).
From the observations and kinetic considerations above, we conclude that it is
challenging to design scavengers of MG that compete effectively with Glo1. Therefore,
optimum therapeutic intervention is likely with Glo1 inducers – particularly reversing down
regulation of Glo1 expression in obesity and diabetes.
Glo1 inducers
When surveying the regulatory elements of the mammalian GLO1 gene to exploit for
induction of increased Glo1 expression, the functional ARE was a prime choice. Basal and
inducible expression of Glo1 is thereby regulated by Nrf2 (193). A Glo1 inducer directed to
Nrf2 would also likely have beneficial off-target effects on other ARE-linked genes. As the
regulatory mechanism of Nrf2 remains unclear, we developed and applied a functional screen
for Glo1 inducer activity using a luciferase reporter linked to the functional GLO1-ARE
motif. Small molecule activators of Nrf2 were required for screening. We sought to develop
Glo1 inducer therapeutic agents for treatment of obesity and diabetes and their complications.
Regulatory agencies require prospective novel drugs to have very low frequency of adverse
effects for these therapeutics applications and so we restricted our Glo1 inducer search to
dietary bioactive compounds which often have known high tolerability and low risk of
adverse effects. Dietary bioactive compound selection criteria were: ability to activate Nrf2 at
concentrations achieved or likely achievable at tolerable doses clinically and/or decrease
glycation and/or toxicity by MG or similar compounds. GLO1-ARE and functionally inactive
mutated GLO1-ARE luciferase stable transfectant cell lines were incubated with and without
bioactive compounds (0.625 – 20.0 μM) for 6 h.  Early in our studies we found 10 μM trans-
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resveratrol (tRES) gave a strong Glo1 inducer response and so we normalised Glo1 inducer
activity in the screening assay to this as the positive control (193). Nrf2-dependent Glo1
transcriptional response was verified by siRNA silencing of Nrf2. Screening hit criteria were:
increased transcriptional response at ≤5 μM without significant cytotoxicity to human cells in 
primary culture. Human aortal endothelial cells (HAECs) and BJ fibroblasts were used.
For the Glo1 inducer activity screening studies in vitro, the bioactive compound
giving the lowest median effective concentration EC50 for GLO1-ARE transcriptional activity
was hesperetin (HESP) for which EC50 = 0.59 µM and Emax 24.4%. The bioactive compound
giving the highest Emax was tRES for EC50 = 2.52 µM and Emax 100 % (195). The Glo1 inducer
response was validated by assessment of Glo1 mRNA and Glo1 protein in human cell lines and
primary cultures. To enhance the pharmacological efficacy we studied the synergism of tRES
and HESP together. Study of the GLO1-ARE transcriptional response of 5 µM HESP with
0.625 – 10 µM tRES showed that HESP combined synergistically with tRES, decreasing the
EC50 of tRES to 1.46 µM whilst maintaining the Emax, lifting the Glo1 induction response to
high levels with clinically achievable concentration range for both compounds. The predicted
increase of GLO1-ARE transcriptional response of 0.1 – 1.0 tRES in the presence of 5 µM
HESP was 3 – 79 fold, including up to 79% increased GLO1-ARE transcriptional response over
additive effects. This suggested improved pharmacological efficacy and decreased risk of
toxicity may be achieved in clinical translation from use of a tRES-HESP co-formulation
through pharmacological additive and synergistic effects (195).
Others compounds with Glo1 inducer activity are: allyl isothiocyanate (AITC) and
sulforaphane (SFN), butylated hydroxyanisole (BHA) and n-3 polyunsaturated fatty acids
(PUFA) – Table 1. SFN and AITC have a relatively narrow therapeutic window and BHA
and PUFA have relatively low potency.
Clinical evaluation of glyoxalase 1 inducer, tRES-HESP
The Glo1 inducer, tRES-HESP, was evaluated in a recent clinical study of healthy
overweight and obese subjects. The study was a randomized, double blind, placebo-
controlled crossover study in 29 subjects. Dosing was by oral capsule, once daily, containing
90 mg tRES-120 mg HESP or placebo. Dosing periods were 8 weeks with 6 weeks washout
between in the crossover period. There was high compliance to tRES-HESP treatment and
urinary excretion of tRES and HESP metabolites was increased >2000-fold and >100 fold,
respectively, compared to placebo. Food consumption was similar throughout the study.
Clinical safety indicators were normal at study entry and remained unchanged throughout the
placebo and tRES-HESP treatment periods.
tRES-HESP treatment produced a 22% increase in Glo1 activity of peripheral blood
mononuclear cells (PBMCs) of all subjects, compared to placebo in all subjects. The increase was
27% in highly overweight subjects – defined as subjects with BMI > 27.5 kg/m2, and 30% in obese
subjects (with BMI ≥ 30 kg/m2). Most changes were found in highly overweight subjects and
outcomes are presented for this subgroup. Concomitant with increased Glo1 activity, there was a
37% decrease in plasma MG post-supplementation with tRES-HESP but not with placebo. The
whole body flux of MG glycation of proteins was assessed by measuring the urinary excretion
of MG-H1 free adduct, corrected for MG-H1 absorbed from food. The flux of endogenously-
generated MG-H1 adducts was decreased by 14% with tRES-HESP treatment but not with
placebo. MG-H1 is also absorbed from food. The mean proportion of total MG-H1 produced
endogenously was 67%, indicating that in overweight and obese subjects MG-H1 is mainly of
endogenous origin – although this is highly variable (195).
Physiological effects of tRES-HESP treatment were profound. Insulin resistance,
assessed by the Oral Glucose Insulin Sensitivity (OGIS) index, was corrected to levels typical of
lean subjects with normal insulin sensitivity. The increase in OGIS of obese subjects was + 58
ml min-1m-2 which is a change similar to that found with pharmaceutical treatment of
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patients with T2DM (for example, 1.7 g metformin per day, Δ OGIS = +54 ml min-1m-2) (82)
and extreme weight loss with gastric band surgery in morbid obesity (Δ OGIS = +62 ml min-
1m-2) (72). The main contributory factors to this effect were decreased fasting plasma glucose
(FPG) and decreased postprandial plasma glucose. There was a 5% decrease in FPG post
supplementation with tRES-HESP which exceeds that found in similar trials with metformin
and matches that found with Olristat – a lipase inhibitor anti-obesity drug (108,131).
Decrease in FPG in the normal range is associated with reduced risk of developing T2DM
(185). Therefore, tRES-HESP treatment would likely decrease exposure to increased glucose
concentration in the fasting and postprandial states in the highly overweight and obese
populations and decrease risk of developing T2DM (195).
Concomitant with increased metabolic health there were small decreases in BMI and
body weight in the obese subjects with tRES-HESP. There were also suggestions of improved
vascular function, indicated by increased brachial artery flow mediated dilatation response
and decreased plasma vascular inflammation marker sICAM1, and improved renal function –
indicated by both increased estimated glomerular filtration rate and decreased plasma urea
(195).
Gene expression changes of PBMCs with tRES-HESP suggested a profound anti-
inflammatory response: 30% decrease of prostaglandin-endoperoxide synthase 2 (PTGS2 or
COX2) and 39% decrease of interleukin-8 (IL-8). This was maintained in highly overweight
subjects with also 49% decrease in expression of chemokine (C-C motif) ligand 2 (CCL2) or
monocyte chemoattractant protein-1 (MCP-1) and 37% decrease in expression of the receptor
for advanced glycation endproducts (RAGE). In the obesity subgroup there was also decrease
in Kelch-like ECH-associated protein 1 (KEAP1) and tumour necrosis factor-α (TNFA). 
Treatment with placebo produced no change in gene expression of PBMCs (195).
The Glo1 inducer appears to be particularly appropriate and timely for treatment of
high prevalence complications of obesity such as NAFLD. Decreases in expression of
KEAP1 and TNFα will likely also be beneficial in facilitating activation of Nrf2 and 
decreasing insulin resistance, respectively (115,187). Countering insulin resistance and
inflammation are targets for treatment of NAFLD (119) and therefore prospective Glo1
inducer therapy would address multiple treatment targets. These responses are also likely to
be beneficial in clinical diabetes: IL-8 drives renal inflammation (4,172) and PTGS2
increases angiotensin production, renal cell dysfunction and albuminuria (35). Down
regulation of MCP-1 and RAGE both would likely contribute to treatment of diabetic kidney
disease (36,167). Inhibition of MCP-1 and RAGE are alternative strategies for development
of new treatments for diabetic kidney disease which have yet to be proven tractable by direct
inhibitor drug therapy.
Benefit of a synergistic combination of Nrf2 activators
Prior to the HATFF study, tRES and HESP have been evaluated for health benefit individually
but were without similar effect. Synergistic combination of Nrf2 activators was crucial to
successful clinical translation of Nrf2 activators.
There have been many studies on the potential health benefits of tRES – including the
pioneering studies of Sinclair and co-workers (28) and many others, reviewed elsewhere in
this journal (134). Disappointing outcomes have been in clinical translation. From meta-
analysis, it was concluded that tRES alone does not affect glycaemic status in overweight and
obese human subjects (98). Prolonged treatment of patients with T2DM with tRES at doses
approaching the maximum tolerable was without beneficial effect (24). Studies showing
beneficial effects of tRES in diabetes have often been open trials or studies with baseline
difference in treatment and placebo arms suggesting problems with randomization. This may
produce misleading outcomes. Lack of therapeutic effect is at odds with evidence from rodent
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models (28) and is likely due to interspecies differences in pharmacology, host interactions,
and maximum tolerable dose. The maximum tolerable dose of tRES clinically to avoid
adverse effects is <14 mg/kg (48). Evidence for health benefit of tRES in rodent models was
mainly found at doses that markedly exceeded this and so safe clinical translation of tRES
alone is unlikely. HESP has been mostly studied as a metabolite absorbed from clinical
dosing with hesperidin – a related dietary glycoside found in citrus fruits (33). HESP alone also
did not improve plasma glucose nor insulin resistance (157). Use of HESP rather than
hesperidin is likely also crucial since HESP has higher bioavailability than hesperidin and ca.
70-fold greater potency in Nrf2 activation (122).
A mechanistic interpretation of the pharmacological synergism of tRES and HESP came
from consideration of the regulation of Nrf2 as a constitutive translocation oscillator whereby
functional activation of Nrf2 is increased by increasing the frequency of cytoplasmic-nuclear
oscillations of Nrf2 – through increasing the reactivation or refresh rate of Nrf2, and decreasing
the rate of inactivation of Nrf2 in the nucleus (191,192) (Fig. 6). HESP likely drives increased
Nrf2 oscillation frequency through activation of protein kinase A (PKA) and Fyn kinase
downstream at ≥1 µM (75,192,195) and tRES decreases acetylation-driven nuclear inactivation 
of Nrf2 by increasing insitu activity through inhibiting cAMP phosphodiesterases (PDE),
activating AMPK, increasing NAD+ and insitu activity of sirtuin-1 (132); with HESP also
synergising for AMPK activation and sirtuin-1 through the PKA pathway (61,75,132) (Fig. 7).
This is the first time the oscillatory model of Nrf2 regulation has been exploited
pharmacologically to achieve potent transcriptional response at low concentrations of co-
agonists. This enables maximal pharmacological effect at agonist concentrations 50 – 100
fold lower than the minimum concentration inducing toxicity. Synergistic combinations of
small molecule agonists addressing different features of Nrf2 regulation may provide for
successful clinical translation of Nrf2 activator pharmaceutical combination therapeutics.
Although evidence from Glo1 transgenic animal studies suggest correcting down-
regulation of Glo1 in obesity and diabetes is likely to provide treatment for NAFLD and
vascular complications of diabetes, change in expression of other protective genes may
contribute to the therapeutic mechanism of action. tRES-HESP increased expression of ɣ-
glutamylcysteine ligase, catalytic and modulatory subunits GCLC, GCLM, in HAECs, BJ
fibroblasts and HepG2 cells, for example, and increased cellular GSH concentration – which
increases in situ activity of Glo1. Expression of many antioxidant genes were unchanged in
PBMCs of the clinical intervention study, however, whereas Glo1 expression and activity
were increased. Larger clinical studies in the future may have increased statistical power to
detect changes in antioxidant-linked genes.
Mechanism of action of the tRES-HESP Glo1 inducer
tRES-HESP corrected insulin resistance, as judged by increases in the OGIS index. The OGIS
index correlates strongly with the gold-standard method to assess insulin sensitivity, the
hyperinsulinemic-euglycemic clamp technique (41), and is deduced from plasma glucose and
insulin levels in the fasting and glucose-challenge states of an oral glucose tolerance test
(109). OGIS was initially proposed as a marker of insulin resistance but is also improves with
increased β-cell sensitivity to glucose  and decreased glucose absorption (74).  tRES-HESP may 
intervene to correct insulin resistance by activating Nrf2-induced increase in expression of
FGF21 (55). However, obesity is a FGF21-resistant state due to down regulation of the FGF21
receptor cofactor β-Klotho (58). MG-driven protein glycation is implicated in the down 
regulation of  β-Klotho is MG-driven protein (206). By inducing Glo1 expression and 
decreasing MG protein glycation, therefore, we likely corrected the functional deficit of β-
Klotho and re-engaged FGF21. This is expected to improve insulin sensitivity and stimulate
browning of WAT, potentiate fatty acid storage and oxidation in brown adipose tissue (47,110).
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A characteristic of increased β-Klotho expression and activity was its blocking of inflammatory 
signalling to down regulate expression of pro-inflammatory mediators IL8, MCP-1, ICAM1
and RAGE (206), and via decreasing MCP-1 also suppresses expression of PTGS2 (56).
Remarkably these were the exact features of the transcriptional signature found in PBMCs with
tRES-HESP treatment (195).
For pancreatic beta-cell sensitivity to glucose, the pancreatic islet is also a target of
FGF21 and displays decreased reduced β-Klotho expression and resistance to FGF21 in 
obesity and diabetes leading to decreased β-cell function and cell mass (166). Increasing β-
Klotho expression was associated with conservation of β-cells mass, and increased insulin 
storage and glucose-stimulated insulin secretion response (95). tRES (7 mg/kg) improved
beta-cell function in nonhuman primates given a high-fat/high-sugar diet (50). Lower doses of
tRES may synergise with HESP to produce similar effect.
The positive correlation of tRES-HESP therapeutic potency with increasing BMI in
overweight and obese subjects is consistent with the correction of metabolic dysfunction to
regain that of lean controls rather than imposition of a pharmacological response in all
subjects. This could relate to correction of β-Klotho inactivation to normal levels. Lack of 
effect in healthy subjects of BMI close to the upper limit of the lean range suggests lack of an
anorexic adverse effect.
There may be pre-systemic effects of the tRES-HESP treatment. An extremely high
dose of HESP, ca.500 mg/kg, impaired digestion of starch and changed the composition of
gut microbiota in rats (186) but this may not apply to the markedly lower clinical dose of
HESP in the HATFF study (ca.1.3 mg/kg HESP). tRES at the clinically maximum tolerable
dose (15 mg/kg) did not affect the composition of gut microbiota in high fat-sucrose fed rats
(49). Also of relevance is activation of AMPK and sirtuin-1 by 20 – 40 μM tRES infused in the 
duodenum which initiated a gut–brain–liver neuronal axis that improved hypothalamic
insulin sensitivity and decreased hepatic glucose production (37). This may be potentiated by
HESP co-administration.
The major site in the body where HESP and tRES are at relatively high concentration
is the stomach and, for a short time after administration, the small intestinal. At the latter site,
tRES and HESP are absorbed and rapidly conjugated to mainly glucuronides and also to a
lesser extent sulfates (27,165). Conjugates may be secreted on the apical and basolateral sides
into the gut lumen and portal venous circulation, respectively. Studies of HESP infusion into
the small intestine have shown that the absorption of free HESP is limited by this conjugation
which is overwhelmed by 120 µM HESP and increased unconjugated HESP is then absorbed
(165). As tRES also draws on the capacity of the small intestine epithelium for conjugation,
co-presence of ≥ 120 µM HESP may permit increased absorption of tRES. After an average 
meal, the mean stomach volume of a healthy human subject is 0.94 litres. With 90 mg tRES
and 120 mg HESP, the expected mean concentrations in the stomach lumen are 420 μM for 
both compounds. Gastric emptying occurs approximately 40 min after food and/beverage
ingestion. When tRES is administered alone, the peak plasma concentration of tRES at doses
similar to that used in the HATFF study occurs at ca.50 min post-administration (26). So
when tRES and HESP are given individually, the relatively high concentrations in the small
intestine are short-lived. Co-administration of HESP with tRES likely exhausts or slows the
intestinal conjugation capacity for both agents and facilitates increased absorption of the
unconjugated compounds. This remains to be explored in follow-up pharmacokinetic studies
but is an intriguing strategy to circumvent the problems of limited bioavailability of tRES
(Fig. 8).
Glucose absorption in the porcine jejunum and ileum ex vivo was inhibited ca.50% by
300 μM tRES and so there is potentially pharmacological competence to slow glucose 
absorption for a short period after dosing (68).
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Next steps for development of the tRES-HESP Glo1 inducer for treatment of
complications of obesity and diabetes
In rodent models there is evidence that tRES and HESP or hesperidin alone improve
metabolic health in obesity and prevent diabetic nephropathy but at doses that exceed the
maximum tolerable clinical dose. tRES improved metabolic health in HFD-fed mice at ca.30
- 60 mg/kg (10,17) and improved renal function in rodent models of diabetic nephropathy at
20 - 300 mg/kg (83,86). HESP had moderate anti-obesogenic activity and was evaluated at
ca.500 mg/kg (73) and hesperidin decreased urinary albumin excretion in diabetic rats at 100
and 200 mg/kg (77).
The Glo1 inducer combination may also be considered for prevention of T1DM. tRES
alone has previously been found to be effective in prevention of diabetes in experimental mouse
model of non-obese of type 1 diabetes (NOD) at doses of tRES higher than tolerated
clinically (91).
For further development of tRES-HESP combination therapy there is a regulatory
requirement to show synergistic therapy in an appropriate animal model at clinically
translatable doses. The challenge now is to demonstrate synergism of tRES and HESP in
rodent models for prevention of weight gain and NAFLD in obesity and treatment of
nephropathy and other vascular complications in experimental diabetes. In reverse translation
of the outcomes of the HATFF study, the chances of success look good. A clinical phase 2
trial for diabetic would then be viable.
Concluding remarks
Dicarbonyl stress is a dysfunctional metabolic state that appears to have a key role in the
development of obesity, diabetes and related metabolic and vascular complications. It is
intrinsically linked to oxidative stress but may also be established and produce protein and
DNA damage non-oxidatively. The recent emergence of a strategy to counter dicarbonyl
stress with Glo1 inducers has shown promise in early clinical evaluation and builds on a
wealth of knowledge accumulated on dietary bioactive compounds - particularly tRES.
Innovation
New and improved treatments for complications of obesity and diabetes, such as NAFLD and
diabetic kidney disease, area required. Functional genomics and related studies in
experimental obesity and diabetes suggest the dysfunctional metabolic state of “dicarbonyl
stress”, exemplify by increased levels of MG, is found in plasma and at sites of metabolic and
vascular complications development in obesity and diabetes. Studies in animal models
suggest increasing expression of glyoxalase 1 (Glo1) corrects dicarbonyl stress and prevents
complications of obesity and diabetes. trans-Resveratrol and hesperetin in combination
inducer increased expression of Glo1.
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TABLE 1. Compounds with Glo1 inducer activity.
Glo1 inducer Dose/concentration; organism or cell Effect
AITC 2 µM; HepG2 cells Glo1 activity increased ca.2-fold. (193)
BHA 200 mg/kg; C57BL/6J mice Glo1 mRNA increased 2-fold in small intestine of wild-
type mice but not in Nrf2 knockout mice.
(120)
HESP 5 µM; HAEC, BJ fibroblast and HepG2 cells in vitro Glo1 mRNA and protein increased 20 – 40% (195)
n-3 PUFA 10% total fat as n-3 PUFA; C57BL/6 mice Glo1 protein increased +67% in liver. (5)
tRES 50 µM; HepG2 cells Glo1 protein increased +38%. (34)
5 µM; HAECs, BJ fibroblasts and HepG2 cells in vitro Glo1 mRNA and protein increased 20 – 30% (195)
tRES-HESP
combination
5 µM tRES+5 µM HESP; HAECs, BJ fibroblasts and
HepG2 cells in vitro
Glo1 mRNA and protein increased 20 – 40%
(195)90 mg tRES and 120 mg HESP, o.d.; overweight and
obsess healthy human subjects
PBMC Glo1 activity increased 30%.
SFN 2 – 8 µM; HepG2 cells and BJ fibroblasts in vitro Glo1 mRNA, protein and activity increased ca.2-fold. (193)




FIG. 1 Metabolism of methylglyoxal by the glyoxalase system. Schematic representation
of the glyoxalase metabolic pathway. Reproduced with permission from (153).
FIG. 2 Formation of methylglyoxal, metabolism and glycation of protein and DNA in
vivo. Tissue levels of MG and MG-H1 adduct residues in tissues are given for mice. PBMC
DNA AGEs are for human subjects and flux of MG metabolised by the glyoxalase system
and urinary excretion of MG-H1 free adduct is for healthy adduct humans. Data from
(60,88,148,152,182,195). The figure is reproduced with permission from (152).
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FIG. 3 Increased formation of methylglyoxal in the triglyceride/free fatty acid cycle.
Percentage flux of glyceroneogenesis in triglyceride formation in liver and adipose tissue is
from (125). Abbreviations: DHAP, dihydroxyacetonephosphate; FFA, free fatty acids; GA3P,
glyceraldehyde-3-phospahte; TG, triglyceride. The figure is reproduced with permission from
(111).
FIG. 4 Whole blood concentration of methylglyoxal in patients with type1 and type 2
diabetes and healthy controls Data replotted with permission from (113).
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FIG. 5. Dicarbonyl scavengers. Examples of scavenging reactions are given for MG. A.
Aminoguanidine. B. Metformin. C. N-Phenacylthiazolium bromide. D. Arginine-rich
peptides – an arginine residue is shown. E. Histidine residue glyoxalase mimetic scavengers.
See also (16,20,23,28,84,85,100,159,179,183).
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FIG. 6. Oscillatory model for Nrf2 regulation. Numbers relate to point in the oscillation cycle: 1. Nrf2/Keap1/PGAM5 ternary complex is
disrupted by overshoot, Nrf2 enters the nucleus with release of free PGAM5 →  activation of Fyn; 2. Phosphorylation and dephosphorylation of 
Fyn enables ultra-sensitivity, delayed and gradual build-up and then rapid influx of activated Fyn into the nucleus; 3. ARE-directed
transcriptional response by Nrf2, then inactivation of nuclear Nrf2 by acetylation; 4. Fyn phosphorylates nuclear Nrf2 and drives its rapid
expulsion from the nucleus ready for the cycle to repeat, coordinated rapid exit of Nrf2 from the nucleus; 5. Nrf2 rebinds Keap1 and PGAM5 in
the ternary complex but at a level greater than equilibrium. The model reproduces key features of experimental observations: asymmetric
oscillations and faster oscillations of decreased amplitude when stimulated (191). A stochastic version simulated using the Gillespie algorithm
gave simulations that qualitatively match experimental time course profiles and transcriptional response. Abbreviation: Ac, acetylation; AcT,
acetyl-transferase; aFyn, activation Fyn kinase; CK2, casein kinase-2; Cul-3, Cullin-3; E2, ubiquitin ligase; maf, small maf protein – accessory
proteins for Nrf2 activation; P, phosphorylation; PGAM5, mitochondrial serine/threonine-protein phosphatase; PKA, cAMP-dependent protein
kinase; Ub, ubiquitin. Figure reproduced with minor modifications and permission from (192).
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FIG. 7 Pharmacological synergism of trans-resveratrol and hesperetin to activate
sirtuin-1 and fyn kinase. See (61,75,132,191,196,198). Abbreviations: PDE,
phosphodiesterase; Epac1, exchange factor directly activated by cAMP 1; ER/SR,
endoplasmic reticulum/sarcoplasmic reticulum; CamKKβ, Ca2+/calmodulin-dependent
protein kinase kinase-β; AMPK, AMP-activated protein kinase; NAM, nicotinamide; 2’-
OAADPr, 3'-O-acetyl-ADP-ribose; PKA, protein kinase A; Fyn, Fyn kinase; P,
phosphorylation.
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FIG. 8 Impairment of glucuronidation of trans-resveratrol and hesperetin in the small
intestine by co-administration at pharmaceutical doses. Is this how to circumvent the
limited bioavailability of resveratrol problem? Comparison of the demands on
glucuronidation in the intestinal epithelium when tRES alone or in combination with HESP
are administered. Abbreviations: HESP-3’-O-G, hesperetin-3’-O-glucuronide; HESP-7-O-G,
hesperetin-7-O-glucuronide; tRES-3-O-G, trans-resveratrol-3-O-glucuronide; tRES-4’-O-G,
trans-resveratrol-4’-O-glucuronide.
